Suba Krishnan
Overview
Explore the profile of Suba Krishnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
1652
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reardon D, Kim T, Frenel J, Simonelli M, Lopez J, Subramaniam D, et al.
Cancer
. 2021 Jan;
127(10):1620-1629.
PMID: 33496357
Background: Current treatments for recurrent glioblastoma offer limited benefit. The authors report the antitumor activity and safety of the anti-programmed death 1 (anti-PD-1) immunotherapy, pembrolizumab, in programmed death ligand 1...
2.
Piha-Paul S, Oh D, Ueno M, Malka D, Chung H, Nagrial A, et al.
Int J Cancer
. 2020 May;
147(8):2190-2198.
PMID: 32359091
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years...
3.
Chung H, Piha-Paul S, Lopez-Martin J, Schellens J, Kao S, Miller Jr W, et al.
J Thorac Oncol
. 2019 Dec;
15(4):618-627.
PMID: 31870883
Introduction: Pembrolizumab has shown clinical benefit in patients with previously treated recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806) and the phase 2 multicohort study KEYNOTE-158...
4.
Callahan M, Kluger H, Postow M, Segal N, Lesokhin A, Atkins M, et al.
J Clin Oncol
. 2017 Oct;
36(4):391-398.
PMID: 29040030
Purpose The clinical activity observed in a phase I dose-escalation study of concurrent therapy with nivolumab (NIVO) and ipilimumab (IPI) in patients with previously treated or untreated advanced melanoma led...
5.
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al.
Lancet Oncol
. 2017 Jan;
18(3):312-322.
PMID: 28131785
Background: Patients with metastatic urothelial carcinoma have a dismal prognosis and few treatment options after first-line chemotherapy. Responses to second-line treatment are uncommon. We assessed nivolumab, a fully human IgG4...
6.
Segal N, Logan T, Hodi F, McDermott D, Melero I, Hamid O, et al.
Clin Cancer Res
. 2016 Nov;
23(8):1929-1936.
PMID: 27756788
Urelumab is an agonist antibody to CD137 with potential application as an immuno-oncology therapeutic. Data were analyzed to assess safety, tolerability, and pharmacodynamic activity of urelumab, including the dose selected...
7.
Setty B, Key N, Rao A, Gayen-Betal S, Krishnan S, Dampier C, et al.
Br J Haematol
. 2012 Feb;
157(3):370-80.
PMID: 22360627
Tissue Factor (TF) initiates thrombin generation, and whole blood TF (WBTF) is elevated in sickle cell disease (SCD). We sought to identify the presence of TF-positive monocytes in SCD and...
8.
Quinn C, Stuart M, Kesler K, Ataga K, Wang W, Styles L, et al.
Br J Haematol
. 2011 Aug;
155(2):263-7.
PMID: 21848879
Tapered oral dexamethasone for acute chest syndrome (ACS) in sickle cell anaemia was studied using a novel ACS assessment tool and investigational biomarkers. Twelve participants were randomized (mean age 17·3...
9.
Krishnan S, Setty Y, Betal S, Vijender V, Rao K, Dampier C, et al.
Br J Haematol
. 2009 Dec;
148(5):797-804.
PMID: 19995398
Several lines of evidence suggest that sickle cell disease (SCD) is associated with a chronic inflammatory state. In this study of 70 children with SCD at steady state evaluated by...
10.
Krishnan S, Siegel J, Pullen Jr G, Hevelow M, Dampier C, Stuart M
Thromb Res
. 2008 Jan;
122(4):455-8.
PMID: 18230405
We evaluated vWF profiles in children and adolescents with SCD and sleep hypoxemia. Mean vWF:Ag levels were significantly elevated in the SCD-hypoxemia group when compared with SCD-normoxia and control groups...